Hyponatraemia secondary to nivolumab-induced primary adrenal failure
Checkpoint inhibitors, such as ipilimumab and pembrolizumab, have transformed the prognosis for patients with advanced malignant melanoma and squamous non-small-cell lung cancer, and their use will only expand as experience is gained in a variety of other malignancies, for instance, renal and lympho...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2016-11-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-16-0108 |
id |
doaj-2745e36a2f504d67b9be2672418f3b56 |
---|---|
record_format |
Article |
spelling |
doaj-2745e36a2f504d67b9be2672418f3b562020-11-25T02:43:29ZengBioscientificaEndocrinology, Diabetes & Metabolism Case Reports2052-05732052-05732016-11-01111410.1530/EDM-16-0108Hyponatraemia secondary to nivolumab-induced primary adrenal failureHarris Trainer0Paul Hulse1Claire E Higham2Peter Trainer3Paul Lorigan4Department of Endocrinology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKDepartment of Radiology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKDepartment of Endocrinology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKDepartment of Endocrinology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKDepartment of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UKCheckpoint inhibitors, such as ipilimumab and pembrolizumab, have transformed the prognosis for patients with advanced malignant melanoma and squamous non-small-cell lung cancer, and their use will only expand as experience is gained in a variety of other malignancies, for instance, renal and lymphoma. As the use of checkpoint inhibitors increases, so too will the incidence of their unique side effects, termed immune-related adverse events (irAEs), which can affect dermatological, gastrointestinal, hepatic, endocrine and other systems. Nivolumab is a monoclonal antibody that blocks the human programmed death receptor-1 ligand (PD-L1) found on many cancer cells and is licensed for the treatment of advanced malignant melanoma. We describe the first case of nivolumab-induced adrenalitis resulting in primary adrenal failure presenting with hyponatraemia in a 43-year-old man with malignant melanoma. The case highlights the potentially life-threatening complications of checkpoint inhibitors and the need for patient education and awareness of irAEs among the wider clinical community because such side effects require prompt recognition and treatment.https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-16-0108 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Harris Trainer Paul Hulse Claire E Higham Peter Trainer Paul Lorigan |
spellingShingle |
Harris Trainer Paul Hulse Claire E Higham Peter Trainer Paul Lorigan Hyponatraemia secondary to nivolumab-induced primary adrenal failure Endocrinology, Diabetes & Metabolism Case Reports |
author_facet |
Harris Trainer Paul Hulse Claire E Higham Peter Trainer Paul Lorigan |
author_sort |
Harris Trainer |
title |
Hyponatraemia secondary to nivolumab-induced primary adrenal failure |
title_short |
Hyponatraemia secondary to nivolumab-induced primary adrenal failure |
title_full |
Hyponatraemia secondary to nivolumab-induced primary adrenal failure |
title_fullStr |
Hyponatraemia secondary to nivolumab-induced primary adrenal failure |
title_full_unstemmed |
Hyponatraemia secondary to nivolumab-induced primary adrenal failure |
title_sort |
hyponatraemia secondary to nivolumab-induced primary adrenal failure |
publisher |
Bioscientifica |
series |
Endocrinology, Diabetes & Metabolism Case Reports |
issn |
2052-0573 2052-0573 |
publishDate |
2016-11-01 |
description |
Checkpoint inhibitors, such as ipilimumab and pembrolizumab, have transformed the prognosis for patients with advanced malignant melanoma and squamous non-small-cell lung cancer, and their use will only expand as experience is gained in a variety of other malignancies, for instance, renal and lymphoma. As the use of checkpoint inhibitors increases, so too will the incidence of their unique side effects, termed immune-related adverse events (irAEs), which can affect dermatological, gastrointestinal, hepatic, endocrine and other systems. Nivolumab is a monoclonal antibody that blocks the human programmed death receptor-1 ligand (PD-L1) found on many cancer cells and is licensed for the treatment of advanced malignant melanoma. We describe the first case of nivolumab-induced adrenalitis resulting in primary adrenal failure presenting with hyponatraemia in a 43-year-old man with malignant melanoma. The case highlights the potentially life-threatening complications of checkpoint inhibitors and the need for patient education and awareness of irAEs among the wider clinical community because such side effects require prompt recognition and treatment. |
url |
https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-16-0108 |
work_keys_str_mv |
AT harristrainer hyponatraemiasecondarytonivolumabinducedprimaryadrenalfailure AT paulhulse hyponatraemiasecondarytonivolumabinducedprimaryadrenalfailure AT claireehigham hyponatraemiasecondarytonivolumabinducedprimaryadrenalfailure AT petertrainer hyponatraemiasecondarytonivolumabinducedprimaryadrenalfailure AT paullorigan hyponatraemiasecondarytonivolumabinducedprimaryadrenalfailure |
_version_ |
1724769008995008512 |